Nascent Biotech Beheer
Beheer criteriumcontroles 4/4
Nascent Biotech's CEO is Sean Carrick, appointed in Mar 2015, has a tenure of 9.67 years. total yearly compensation is $252.00K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 13.39% of the company’s shares, worth $1.85M. The average tenure of the management team and the board of directors is 9.7 years and 9.3 years respectively.
Belangrijke informatie
Sean Carrick
Algemeen directeur
US$252.0k
Totale compensatie
| Percentage CEO-salaris | 100.0% |
| Dienstverband CEO | 9.7yrs |
| Eigendom CEO | 13.4% |
| Management gemiddelde ambtstermijn | 9.7yrs |
| Gemiddelde ambtstermijn bestuur | 9.3yrs |
Recente managementupdates
Recent updates
Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$2m |
| Mar 31 2024 | US$252k | US$252k | -US$2m |
| Dec 31 2023 | n/a | n/a | -US$2m |
| Sep 30 2023 | n/a | n/a | -US$3m |
| Jun 30 2023 | n/a | n/a | -US$2m |
| Mar 31 2023 | US$252k | US$252k | -US$3m |
| Dec 31 2022 | n/a | n/a | -US$3m |
| Sep 30 2022 | n/a | n/a | -US$1m |
| Jun 30 2022 | n/a | n/a | -US$1m |
| Mar 31 2022 | US$252k | US$252k | -US$470k |
| Dec 31 2021 | n/a | n/a | US$319k |
| Sep 30 2021 | n/a | n/a | -US$998k |
| Jun 30 2021 | n/a | n/a | -US$1m |
| Mar 31 2021 | US$352k | US$252k | -US$959k |
| Dec 31 2020 | n/a | n/a | -US$4m |
| Sep 30 2020 | n/a | n/a | -US$4m |
| Jun 30 2020 | n/a | n/a | -US$4m |
| Mar 31 2020 | US$323k | US$250k | -US$4m |
| Dec 31 2019 | n/a | n/a | -US$1m |
| Sep 30 2019 | n/a | n/a | -US$1m |
| Jun 30 2019 | n/a | n/a | -US$1m |
| Mar 31 2019 | US$262k | US$186k | -US$1m |
| Dec 31 2018 | n/a | n/a | -US$2m |
| Sep 30 2018 | n/a | n/a | -US$2m |
| Jun 30 2018 | n/a | n/a | -US$2m |
| Mar 31 2018 | US$151k | US$151k | -US$2m |
Compensatie versus markt: Sean's total compensation ($USD252.00K) is below average for companies of similar size in the US market ($USD655.65K).
Compensatie versus inkomsten: Sean's compensation has been consistent with company performance over the past year.
CEO
Sean Carrick (56 yo)
9.7yrs
Tenure
US$252,000
Compensatie
Mr. Sean Carrick has been the President of Nascent Biotech, Inc. since March 9, 2015 and serves as its Chief Executive Officer and Secretary. Mr. Carrick has been Director of Nascent Biotech, Inc. since Ju...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 9.7yrs | US$252.00k | 13.39% $ 1.9m | |
| CFO, Chief Accounting Officer & Director | 10.5yrs | US$180.00k | 6.95% $ 960.4k | |
| Founder | no data | US$43.00k | geen gegevens | |
| Chief Medical Consultant | 4.4yrs | geen gegevens | geen gegevens |
9.7yrs
Gemiddelde duur
72yo
Gemiddelde leeftijd
Ervaren management: NBIO's management team is seasoned and experienced (9.7 years average tenure).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 10.3yrs | US$252.00k | 13.39% $ 1.9m | |
| CFO, Chief Accounting Officer & Director | 10.3yrs | US$180.00k | 6.95% $ 960.4k | |
| Member of Scientific Advisory Board | 9.3yrs | geen gegevens | geen gegevens | |
| Independent Director | 8.6yrs | US$20.00k | 1.05% $ 145.7k | |
| Member of Scientific Advisory Board | 1.9yrs | geen gegevens | geen gegevens |
9.3yrs
Gemiddelde duur
59yo
Gemiddelde leeftijd
Ervaren bestuur: NBIO's board of directors are considered experienced (9.3 years average tenure).